Update on the PepGen Inc. Class Action Lawsuit
Levi & Korsinsky, LLP has taken significant steps to notify investors in PepGen Inc. of a class action securities lawsuit aimed at protecting shareholders' interests. Investors should be aware that the lawsuit concerns allegations of securities fraud that impacted investors during a defined time frame.
Understanding the Class Action Lawsuit
The lawsuit has been initiated to recover financial losses incurred by investors of PepGen Inc. These allegations center around claims that the company misrepresented the effectiveness and safety of its leading product candidate, PGN-EDO51, and provided misleading information about clinical trial results.
Key Allegations and Implications
According to the allegations, the defendants within the company were accused of making false statements regarding several important points: the efficacy of their product in clinical settings, the safety of the CONNECT2 study, and the overall prospects for regulatory approval. Such claims raise concerns about the transparency of PepGen’s communications with its investors.
Timeline of the Allegations
The class action lawsuit targets actions that allegedly occurred between March 7, 2024, and March 3, 2025. Investors affected during this period may have standing to recover losses resulting from these actions. Affected investors should consider joining the lawsuit to ensure their rights are protected.
What Investors Need to Know
If you incurred losses in your investments in PepGen Inc., it is essential to be informed about the options available to you. Those looking to be considered as lead plaintiff must do so by the specified deadline of August 8, 2025. However, note that participation in any recovery does not require serving as a lead plaintiff.
No-Cost Participation
One of the most significant aspects of this class action is that if you qualify as a class member, you may be eligible for compensation without any out-of-pocket costs. This fact ensures that shareholders are not left footing the bill for their involvement in seeking justice.
Why Choose Levi & Korsinsky
Levi & Korsinsky, LLP has amassed a noteworthy history of success over the past two decades. The firm specializes in representing investors in complex securities litigation, and with a dedicated team of over 70 employees, they aim to provide top-notch legal representation for shareholders. Notably, Levi & Korsinsky has been recognized continuously as a leading firm in the area of securities litigation.
Contact Information
If you are seeking more information regarding the lawsuit or wish to discuss your case, you can reach out to Levi & Korsinsky directly. The firm is available for consultations to assist potential claimants through this process.
Located at 33 Whitehall Street, 17th Floor, New York, NY 10004, you can contact them by phone at (212) 363-7500 for inquiries regarding the case or further information about the legal process involved.
Frequently Asked Questions
What is the reason for the class action lawsuit?
The lawsuit primarily aims to address allegations of securities fraud involving misrepresentations regarding PepGen Inc.'s product and clinical trials.
Who can participate in the lawsuit?
Any investor who suffered financial losses in PepGen Inc. shares during the specified period may be eligible to join the lawsuit.
What are the risks of not participating?
Delaying action may mean losing the opportunity to recover losses from the alleged misconduct of those managing the company.
Will it cost me anything to join the lawsuit?
No, class members are not required to pay any upfront fees to participate in the lawsuit.
Who should I contact for more information?
Investors can reach out to Levi & Korsinsky, LLP directly for more information or assistance regarding participation in the class action lawsuit.
